Operating Expenses: SG and A and R and D — Spending to Sustain vs Spending to Grow

Canonical data. Figures tie to Wexford Instruments (USD millions). Ratio conventions follow the Pillar 24 hub.

Some of that spending keeps the business where it is. Some of it is an investment in a business that does not exist yet. Both are subtracted from this year's profit in exactly the same way, which means the income statement systematically makes the company investing in its future look worse than the one harvesting its past. Understanding that asymmetry is most of what this line is for.

What sits here

Selling, general and administrative expenses (SG&A) covers sales and marketing, executive and head-office costs, finance, legal, HR, and facilities. It is the broadest line in the statements and the least uniform between companies.

Research and development covers spending on new and improved products. Under US GAAP it is generally expensed as incurred; under IFRS, development costs meeting specified criteria must be capitalised — a framework difference that on the earlier illustration moved reported operating income by 16%.

Depreciation and amortisation appears here when it is not allocated into cost of goods sold — and where it sits is a company choice, which the gross margin article showed can move gross margin by more than four percentage points without changing operating income at all.

A structural caution before any comparison: the boundary between COGS and operating expenses is not standardised, and neither is what companies bundle inside SG&A. A line labelled the same at two companies may contain quite different things.

Maintenance and investment, expensed identically

This is the article's central point. Consider what is inside SG&A at a growing company: salespeople serving existing customers, and salespeople opening territories that will produce nothing for two years. The first is the cost of this year's revenue. The second is an investment — and it is charged in full against this year's profit. Research and development is the clearest case, since almost all of it is spending now for revenue later, and under US GAAP almost all of it is expensed immediately.

The consequence is uncomfortable and worth stating directly. Take two identical companies. One spends heavily on research and market development; the other spends nothing and harvests what it already has. The second reports higher profit, higher margins, and better returns — this year, and for several years. Nothing in the income statement distinguishes a company underinvesting from a company that is simply efficient, and the accounting is not wrong: the future benefit is genuinely uncertain, which is exactly why standard-setters are reluctant to let companies put it on the balance sheet. But a reader who treats operating margin as a quality score will systematically prefer the company running its assets down.

The practical response is to look at the composition and the trend rather than the total. Research spending as a percentage of revenue, held over several years, says something about commitment; a sudden fall in it flatters current profit at the expense of later years, and a sudden rise depresses current profit for reasons that may be entirely sound.

Operating leverage: the other thing this line reveals

Operating expenses are more fixed than cost of goods sold. Head office, systems, and much of the sales structure do not scale one-for-one with volume, so when revenue grows, these costs often grow more slowly — and operating margin expands without anything improving in the product. That is operating leverage, and it works in reverse too: when revenue falls, fixed costs do not, and margins compress faster than sales.

The test is simple: compare the growth rate of each expense line with the growth rate of revenue. Slower means leverage; faster means the cost base is outrunning the business; equal means the company is scaling proportionally and any margin change came from somewhere else.